Serenoa repens, cucurbita pepo, lycopene and selenium as an adjunct to the treatment of chronic bacterial prostatitis with antibiotics

Serenoa repens, cucurbita pepo, lycopene and selenium as an adjunct to the treatment of chronic bacterial prostatitis with antibiotics: a placebo-controlled, double-blind, randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10248199

Enrollment

128

Registered

2017-10-05

Start date

2017-11-01

Completion date

Unknown

Last updated

2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic bacterial prostatitis and lower urinary tract symptom (LUTS) Urological and Genital Diseases Chronic prostatitis

Interventions

Participants are randomised into two groups (block randomisation, computer generated algorithm). Both groups receive antibiotic treatment for 15 days as a part of their regular treatment of chronic b

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Adult patients with chronic bacterial prostatitis

Exclusion criteria

Exclusion criteria: 1. Patients who are immediately diagnosed during their visit with acute bacterial prostatitis (NIH Category I) 2. Patients who receive treatment with an a-blocker (Terazosin, Doxazosin, Tamsulosin, Alfuzosin) 3. Patients who have been under treatment with antibiotics through the last 6 months 4. Patients who are under treatment with immunosuppressant drugs 5. Patients who are under treatment with drugs containing cortisone 6. Patents who are allergic to corn or cucurbita pepo 7. Patents who suffer from diabetes mellitus 8. Patients who had a history of urethral stricture or neurogenic bladder

Design outcomes

Primary

Measure	Time frame
1. Prostatitis symptoms assessed using the National Institute of Health's Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostate Symptom Score (IPSS) at baseline, 1, 3, 6 and 12 months 2. Qmax measured using specific uroflowmetry techniques at baseline, 3, 6 and 12 months 3. Residual volume after urination and prostate volume measured by the urologist using ultrasound at baseline, 3, 6 and 12 months	—

Measure

Time frame

1. Prostatitis symptoms assessed using the National Institute of Health's Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostate Symptom Score (IPSS) at baseline, 1, 3, 6 and 12 months 2. Qmax measured using specific uroflowmetry techniques at baseline, 3, 6 and 12 months 3. Residual volume after urination and prostate volume measured by the urologist using ultrasound at baseline, 3, 6 and 12 months

—

Secondary

Measure	Time frame
Bacterial reinfection, assessed using Meares - Stamey Test and microbiological testing at baseline, 3, 6 and 12 months	—

Countries

Greece

Contacts

Public ContactBenjamin Polatidis

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026